You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

The man accused of being the driver in 2011’s deadly hit and run case stood in front of a judge on Friday as David Lopez ...

The Bishop Guilfoyle Academy Marauders are a high-powered, high-scoring offensive machine that can feature any one of a half-dozen players taking the lead role in scoring on any particular night. On ...

The Lee Middle and High School Gender and Sexuality Alliance club is celebrating the fourth year of its student-driven No ...

The courtroom Friday afternoon was absolutely packed as dozens showed up to support the Alvidrez family as they faced David Lopez Lilly. This is the first time 37-year-old Lilly is seen in public ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

The top executives of a company accused of abandoning junked wind-turbine blades across Iowa say they shouldn’t be held ...

The S&P 500 jumped 1% on Friday, Jan. 17, 2025, heading into the long weekend on a high note as prospects rebounded for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.